IRIS
MILAN, ENRICO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 127
AS - Asia 123
EU - Europa 66
Totale 316
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 127
CN - Cina 69
SG - Singapore 52
IT - Italia 19
SE - Svezia 18
RU - Federazione Russa 14
FI - Finlandia 9
DE - Germania 3
NL - Olanda 2
HK - Hong Kong 1
IE - Irlanda 1
KG - Kirghizistan 1
Totale 316
Salva come PNG Salva come JPEG
Città #
Singapore 42
Ashburn 24
Shanghai 24
Boardman 13
New York 10
Lawrence 8
Princeton 8
Helsinki 7
Milan 7
Los Angeles 6
Moscow 5
Shenzhen 5
Beijing 4
Guangzhou 4
Washington 3
Wuxi 3
Landshut 2
Lappeenranta 2
Pisa 2
Presezzo 2
Quanzhou 2
Bishkek 1
Clifton 1
Dalian 1
Dallas 1
Dublin 1
Foshan 1
Handan 1
Hangzhou 1
Hong Kong 1
Jiaxing 1
Jinhua 1
Naaldwijk 1
Nanyang 1
Rome 1
San Francisco 1
Seattle 1
Wellesley 1
Yancheng 1
Totale 201
Salva come PNG Salva come JPEG
Nome #
Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) 26
Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 25
Erratum to: Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition) (Autophagy, 12, 1, 1-222, 10.1080/15548627.2015.1100356 24
Autophagy mediates epithelial cancer chemoresistance by reducing p62/SQSTM1 accumulation 24
Autophagy in Plasma Cell Ontogeny and Malignancy 20
Pivotal Advance: Protein synthesis modulates responsiveness of differentiating and malignant plasma cells to proteasome inhibitors 19
A plastic SQSTM1/p62-dependent autophagic reserve maintains proteostasis and determines proteasome inhibitor susceptibility in multiple myeloma cells 19
The Interaction of the Tumor Suppressor FAM46C with p62 and FNDC3 Proteins Integrates Protein and Secretory Homeostasis 19
FAM46C-dependent tuning of endoplasmic reticulum capacity in Multiple Myeloma 17
The amyloidogenic light chain is a stressor that sensitizes plasma cells to proteasome inhibitor toxicity 17
Combined inhibition of p97 and the proteasome causes lethal disruption of the secretory apparatus in multiple myeloma cells 16
MHC Class II Transactivator is an in vivo regulator of osteoclast differentiation and bone homeostasis co-opted from adaptive immunity 16
The Autophagic Process Occurs in Human Bone Metastasis and Implicates Molecular Mechanisms Differently Affected by Rab5a in the Early and Late Stages 15
Original data: "The interaction of the tumor suppressor FAM46C with p62 and FNDC3 proteins integrates protein and secretory homeostasis". Fucci et al. Cell Reports 2020 15
The Immunity-malignancy equilibrium in multiple myeloma: lessons from oncogenic events in plasma cells 14
Single-molecule real-time sequencing of the M protein: Toward personalized medicine in monoclonal gammopathies 14
Plasma cells require autophagy for sustainable immunoglobulin production 14
SAA1 is over-expressed in plasma of non small cell lung cancer patients with poor outcome after treatment with epidermal growth factor receptor tyrosine-kinase inhibitors. 10
Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment 9
Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling 9
A novel proteomic signature of osteoclast differentiation unveils the deubiquitinase UCHL1 as a necessary osteoclastogenic driver 8
TENT5C/FAM46C modulation in vivo reveals a trade-off between antibody secretion and tumor growth in multiple myeloma 3
HMGB1, an evolving pleiotropic protein critical for cellular and tissue homeostasis: role in aging and age-related diseases 2
null 1
Totale 356
Salva come PNG Salva come JPEG
Categoria #
all - tutte 4.378
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 4.378
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20211 0 0 0 0 0 0 1 0 0 0 0 0
2021/20224 0 0 0 1 0 0 1 0 2 0 0 0
2022/202361 18 8 1 0 0 6 2 2 2 21 0 1
2023/2024162 1 13 29 12 14 26 4 20 0 8 7 28
2024/2025120 34 7 24 36 19 0 0 0 0 0 0 0
Totale 356